KIT as a therapeutic target in metastatic melanoma.

By R. Carvajal, C. Antonescu, J. Wolchok, P. Chapman, R. Roman, J. Teitcher, K. Panageas, K. Busam, B. Chmielowski, J. Lutzky and 8 more. Journal of the American Medical Association (JAMA), 2011

806 citations recorded by the source corpus.

Subfields: Gastroenterology, Hematology, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/168d6f18b1ee9c5dad09f93f7d0d30ca3bc9d705

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Hematology

1. Levi A. Garraway
2. S. Baylin
3. Z. Du
4. Christine Lovly

In Molecular Biology

1. Peter W. Laird
2. S. Baylin
3. Eric S. Lander
4. Manel Esteller
5. Timothy Triche
6. Katherine A. Hoadley
7. J. Herman
8. Gad Getz

Citations in the corpus

• Genomic Classification of Cutaneous Melanoma (2015, methodology): “Our classification supports the use of imatinib and dasatinib to treat patients with KITmutated/amplified cutaneous melanomas (Carvajal et al., 2011; Hodi et al., 2008; Lutzky et al., 2008; Terheyden et al., 2010) and consideration of combination therapies with sorafenib, crenolanib, regorafenib,…”
• Mechanisms of receptor tyrosine kinase activation in cancer (2018, positive): “Other RTK amplifications have also been reported in human cancers, including FGFR1 in lung and breast cancer [82, 83], FGFR3 in breast and bladder cancer [84, 85], ERBB4 in breast and gastric cancer [86, 87], FLT3 in colon cancer [88], KIT in melanoma and GIST [89, 90], and PDGFRA in GBM [91].”